Preclinical Pharmacology of ABT‐418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease

Stephen P. Arneric, David J. Anderson, Anthony W. Bannon, Clark A. Briggs, Jerry J. Buccafusco, Jorge D. Brioni, John B. Cannon, Michael W. Decker, Diana Donnelly‐Roberts, Murali Gopalakrishnan, Mark W. Holladay, Jaroslav Kyncl, Kennan C. Marsh, James Pauly, Richard J. Radek, A. David Rodrigues, James P. Sullivan

Research output: Contribution to journalArticlepeer-review

40 Scopus citations
Original languageEnglish
Pages (from-to)1-26
Number of pages26
JournalCNS Drug Reviews
Volume1
Issue number1
DOIs
StatePublished - Mar 1995

Keywords

  • ABT‐418
  • Alzheimer's disease
  • cholinergic channel activator
  • cytoprotection
  • neuronal nicotinic acetylcholine receptor

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Pharmacology

Fingerprint

Dive into the research topics of 'Preclinical Pharmacology of ABT‐418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this